Investing's Big Blindspot. – Sapient Capital sapientcapital.com/insights/inves…

City livability index, March 2024 The Economist

Evidence of dark oxygen production at the abyssal seafloor | Nature Geoscience nature.com/articles/s4156…

Podcast power law The Wall Street Journal

2024 Olympics - 🇺🇸

Why Physics Is Unreasonably Good at Creating New Math - Nautilus nautil.us/why-physics-is…

China healthcare VC deal activity 2014-2024 via PitchBook

Pharma deals fall to lowest level in almost a decade ft.com/content/54a1d8…

Big Pharma’s Bet on China Biotech Is a Rare Trade Bright Spot bloomberg.com/news/articles/…

Excited to share the news of our recently executed option agreement with Duality Biologics. This partnership builds on our growing ambition in oncology and strengthens our ADC portfolio with a potential best-in-class candidate for gastrointestinal cancers.

The relentless advance of American asset managers in Europe via Financial Times on.ft.com/3DkrIUF

With the start of #JPM25, thrilled to share that GSK has just entered into an agreement to acquire IDRx.

Hong Kong IPOs ⁦via Bloomberg⁩

#News for #investors and #media: We’ve announced a collaboration with Hengrui Pharma to develop up to 12 innovative medicines across respiratory, immunology and oncology. Find out more: gsk.to/46AlM6B

Thrilled to share big news from the GSK BD front this morning — we’ve just signed a landmark, multi‑asset collaboration with Hengrui. The two companies will work together to develop up to 12 innovative medicines across respiratory, immunology and oncology. This partnership